They are a molecular genetics cancer diagnostic company formed in 2021 to acquire PharmGenomics GmbH (“PharmGenomics“) with the purpose of commercializing their product portfolio in Europe and the United States. PharmGenomics, a German DIN EN ISO 13485-certified manufacturer of in-vitro diagnostic (“IVD”) tests with its own molecular genetic laboratory, has developed several IVD tests for the European market since it was founded in 2008. Their portfolio consists of the following products and product candidates: ColoAlert, a colorectal cancer (“CRC”) screening stool DNA (“deoxyribonucleic acid”) test licensed from ColoAlert AS and sold in Europe; PancAlert, a product candidate in an early stage of research for a pancreatic cancer screening test based on Real-Time Polymerase Chain Reaction (“PCR”)-based multiplex detection of molecular-genetic biomarkers in stool samples; GenoStrip, a proposed platform technology in an early stage of research to detect pathogens in environments on a molecular genetic basis where a qualitative evaluation must be made in a short-time period; and Legacy Research-Use-Only (“RUO”) and IVD tests, such as the GenoChips and the HumaSense product line, that they intend to license to third parties, sell or discontinue within the coming 18 months as well as third-party laboratory testing that they plan to discontinue.

Industry
Diagnostic - Services-commercial Physical & Biological Research

CEO	CFO
-

Employees	Founded
22	2008

Contacts

Address: Robert Koch Strasse 50 55129 Mainz Germany

Telephone: 0049 6131 5542860

Web page: http://mainzbiomed.com

IPO information

First Trade Date	11/5/2021
Status	Priced
Exchange	NASDAQ
Lockup Period Expiration	.Pro
Quiet Period Expiration	.Pro
Old Price Range	-

Share prices ($)

Shares & Volumes

Shares Initial (MM)	2
Shares Revised (MM)	2
Expected offer amount (MM)	$10
Realized offer amount(MM)	$10

Financial Data (last reporting year)

Market Cap (MM)	$58.55
Revenues (MM)	$0.74
Net Income (Loss) (MM)	$-0.51

Voting

What do you think will happen with the MYNZ share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes:

The lead left underwriter: Boustead Securities

IPOs led by the firm	.Pro
Profitability of conducted IPOs ?	.Pro
1st day change ?	.Pro
Change for the first 3 months ?	.Pro

Underwriters
Boustead Securities
CO-Managers

Sector: Healthcare

Tweets about $MYNZ

Tweets
Tweets volume

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats

Interest over time
Interest by region

Mainz Biomed B.v. (MYNZ)

Buy Bitcoin

Free full financial analysis

IPO Pro-version